Key Points
- Mega-cap tech (Alphabet, Amazon, Qualcomm, AMD, Palantir, Uber) set the tone for Q4 2025 with AI, cloud and digital ad trends driving expectations for another strong but more selective growth phase.
- Obesity and oncology drugs at Eli Lilly, Novo Nordisk, AbbVie and other big pharma names are in focus as investors gauge how durable the weight-loss and specialty-medicine boom is into 2026.
- Energy and industrials (Shell, ConocoPhillips, Linde, Toyota, Mizuho) offer a read on global demand, oil and gas pricing, and capital-return discipline in a more volatile macro environment.
- Consumer franchises at Disney and PepsiCo face scrutiny over streaming profitability, parks growth and resilient snack-and-beverage demand amid slowing global growth.
- Across the week, guidance for 2026 capex, AI infrastructure spending, shareholder returns and margin trajectories may matter more for stock moves than Q4 headline beats or misses.
Macro and sector backdrop
Markets enter this earnings-heavy week debating how much of the AI and GLP‑1–driven profit boom is already in prices and whether 2026 growth can keep pace with 2025. Health care estimates have been cut for many constituents even as a handful of obesity and oncology leaders continue to post outsized revenue gains, heightening dispersion risk within the sector. In tech, investors are watching whether a step‑change in capex for AI and data centers can be matched by monetization in cloud, ads and edge devices without eroding free cash flow. Energy majors are coming off a period of strong cash returns but more modest earnings as commodity prices cooled, making 2026 production and capital‑allocation plans critical. Against this backdrop, the week’s results can reset sector leadership for early 2026 as investors recalibrate expectations around margins, buybacks and capital intensity.
Monday, February 2
Palantir Technologies (PLTR)
Palantir (PLTR) heads into Q4 2025 on a wave of AI enthusiasm after delivering Q3 revenue of about 1.18 billion dollars and non‑GAAP EPS of 0.21 dollars, both above expectations. Management previously guided Q4 revenue to a 1.327–1.331 billion dollar range, implying roughly 61 percent year‑over‑year growth, and raised full‑year revenue guidance to around 4.40 billion dollars. Street estimates cluster near EPS of 0.23 dollars on roughly 1.34 billion dollars of revenue, with investors laser‑focused on U.S. commercial growth and the sustainability of triple‑digit “Rule of 40” metrics. Given the stock’s rich valuation and sharp swings after prior reports, even a beat may not be enough if 2026 AI demand or margin commentary underwhelms.
View the PLTR AI trading bot here: NEM, HWM, GE, MU, PLTR - AI Trading Agent (5 Tickers), 15min
The Walt Disney Company (DIS)
Disney (DIS) reports into an ongoing transition story: streaming profitability, linear‑TV decline, and parks normalization after the post‑pandemic boom. Investors will parse Q4 numbers for streaming subscriber growth and ARPU trends, plus any updated targets on the path to sustained profitability in direct‑to‑consumer. Parks and experiences results will also be key, as this capital‑intensive segment has historically underpinned Disney’s balance sheet and funded content investment. For shareholders, the print could act as a referendum on management’s ability to balance content spend, debt and shareholder returns in a slower‑growth environment.
Mizuho Financial Group (MFG)
Mizuho (MFG) offers a window into Japanese banking at a time of tentative policy normalization and shifting yield curves. Q4 results will be watched for net interest margin expansion, credit costs and fee income from capital markets amid more active global deal flow. Any commentary on capital deployment, cross‑shareholding reductions and shareholder‑return policy could be market‑moving given renewed global interest in Japanese equities.
Teradyne (TER)
Teradyne (TER) sits at the intersection of chip‑cycle dynamics and the long‑term automation trend. After a period of digestion in semiconductor test equipment, investors are looking for signs of an upturn tied to AI‑centric chips and advanced packaging. The Q4 print and 2026 orders outlook will help confirm whether the bottom of this capex cycle is behind the company and how leveraged earnings are to AI server demand.
View the TER AI trading bot here: LRCX, TER, AMAT, KLAC, AMKR, ASML - AI Trading Agent (Semiconductor Manufacturing), 60min
Tuesday, February 3
Advanced Micro Devices (AMD)
AMD (AMD) goes into Q4 2025 as a prime AI‑GPU contender, with the prior quarters marked by strong data‑center growth and a more mixed PC environment. Street expectations bake in robust year‑over‑year revenue gains and improving margins as AI accelerators ramp, with investors focusing on how AI products stack up against dominant incumbents. Guidance around 2026 AI revenue run‑rates and supply capacity could overshadow the headline numbers in driving the stock’s next leg.
View the AMD AI trading bot here: NVDA, AVGO, AMD, TSM, MU - AI Trading Agent (Semiconductors), 60min
Merck & Co. (MRK)
Merck (MRK) remains anchored by oncology stalwart Keytruda and vaccines, but faces mounting patent‑expiry questions later in the decade. Into Q4, analysts have trimmed health‑care estimates broadly, making Merck’s ability to sustain high‑single‑digit or better revenue growth a key watchpoint. Investors will look for pipeline updates and business‑development commentary to bridge the eventual Keytruda patent cliff.
PepsiCo (PEP)
PepsiCo (PEP) has leaned on disciplined pricing and cost control to offset softer volumes in its convenient foods and beverages portfolio. Q4 2024 core EPS grew about 10 percent year over year to 1.96 dollars, beating consensus, even as revenue declined modestly amid subdued category demand and a product recall. For Q4 2025, consensus anticipates another solid earnings performance on disciplined SG&A and productivity, with MarketBeat pointing to an early‑February release and EPS in the mid‑1 dollar range. Guidance for 2026 organic growth and cash returns—PepsiCo planned to return about 8.6 billion dollars to shareholders in 2025—will be central to the stock’s defensive appeal.
Amgen (AMGN)
Amgen (AMGN) is digesting its large Horizon Therapeutics acquisition, which investors view as a swing at accelerating growth. Q4 results should showcase early revenue contribution from acquired assets and the underlying performance of the legacy portfolio. Given competition in key therapeutic areas, the Street will focus on synergy realization, leverage metrics and pipeline catalysts into 2026.
Pfizer (PFE)
Pfizer (PFE) is in the midst of a post‑pandemic reset after COVID‑19 product revenues fell sharply and then rebounded in late 2024. In Q4 2024, Pfizer’s revenue jumped 23 percent year over year, helped by the Seagen acquisition and a roughly 4.1 billion dollar spike in COVID product sales, highlighting the volatility of this revenue stream. For Q4 2025, investors want to see how non‑COVID assets and the Seagen portfolio are offsetting normalization, and whether management can demonstrate a clearer path back to sustainable top‑line growth.
Wednesday, February 4
Alphabet (GOOGL)
Alphabet (GOOGL) anchors mid‑week tech with Q4 2025 results expected to show another step‑up in revenue, from roughly 102.35 billion dollars in the prior quarter to about 111.38 billion dollars. The key debates are around AI‑driven search and YouTube monetization versus rising capital intensity—Google’s capex is seen surging nearly 70 percent in 2025 and another 30 percent in 2026 to about 119 billion dollars. Investors will scrutinize how much higher AI infrastructure spending can go without pressuring free cash flow and returns, and whether the company can maintain discipline on operating expenses.
View the GOOGL AI trading bot here: GOOGL - AI Trading Agent, 15min
Eli Lilly and Company (LLY)
Eli Lilly (LLY) remains at the heart of the obesity‑drug trade, with GLP‑1/GIP therapies and oncology agents driving rapid revenue expansion. Earlier commentary pointed to expected revenue growth of around 32 percent in 2025, with strong contributions from obesity drugs and non‑incretin products like breast‑cancer therapy Verzenio and heart‑failure treatment Jardiance. Zacks estimates Lilly’s oncology portfolio alone at about 2.64 billion dollars in Q4 2025, underlining how diversified the growth engines have become. For investors, the Q4 and guidance package will help gauge how far the GLP‑1 demand curve can run and whether capacity or pricing emerges as a binding constraint.
AbbVie (ABBV)
AbbVie (ABBV) is navigating the post‑Humira era, with Q4 2024 revenue up about 6 percent—the best quarterly increase since late 2021—as next‑gen immunology duo Skyrizi and Rinvoq scale. The company has projected combined sales for these follow‑ons to reach about 31 billion dollars in 2027, a key anchor for medium‑term valuation. Q4 2025 will be dissected for immunology market‑share trends and any updates to the long‑term revenue trajectory as biosimilar competition intensifies.
View the ABBV AI trading bot here: ABBV - AI Trading Agent with corridor TP 3% / SL 2%, 60min
Novartis (NVS)
Novartis (NVS) offers a cleaner, more focused pharma story after years of portfolio pruning. Investors will watch Q4 for continued momentum in innovative medicines and cost discipline, alongside pipeline updates in cardiology, oncology and immunology. With European biopharma valuations lagging some U.S. peers, guidance and capital‑return commentary could influence whether the stock can re‑rate.
Novo Nordisk (NVO)
Novo Nordisk (NVO) reports full‑year 2025 results on February 4, with Morningstar and others emphasizing both the durability and the potential moderation of its weight‑loss blockbuster growth. In prior commentary, Novo projected 2025 revenue growth in the 16–24 percent range, even as it acknowledged some slowdown from breakneck levels. Q4 numbers will be parsed for obesity‑drug capacity, geographic expansion and pricing dynamics, all of which feed directly into expectations for multi‑year cash‑flow compounding.
Uber Technologies (UBER)
Uber (UBER) is set to report Q4 2025 results on February 4, with the Zacks consensus calling for EPS of 0.83 dollars and revenue of about 14.28 billion dollars. That revenue figure implies roughly 19.4 percent year‑over‑year growth, though EPS is expected to fall about 74 percent from the prior year’s unusually strong quarter. Consensus gross bookings for Q4 sit near 53.1 billion dollars, about 20 percent above Q4 2024, and Uber expects adjusted EBITDA of 2.41–2.51 billion dollars, up 31–36 percent year over year. The print will test whether Uber can sustain double‑digit growth while steadily expanding profitability and free cash flow as it matures.
QUALCOMM Incorporated (QCOM)
Qualcomm (QCOM) heads into its fiscal Q1 2026 in strong shape after reporting record QCT (chip) revenues in Q4 FY 2025 of about 9.8 billion dollars, up 13 percent year over year, and total revenue of 11.3 billion dollars. Adjusted EPS in that quarter reached 3.00 dollars, up 12 percent year over year, with auto and IoT revenues growing 27 percent for the full fiscal year. Guidance for Q1 FY 2026 revenue of 11.8–12.6 billion dollars and non‑GAAP EPS of 3.30–3.50 dollars underscored confidence in handset, automotive and edge‑AI demand. For investors, upcoming results will clarify how sustainable non‑Apple revenue growth is and how quickly new AI‑enabled devices can add to the earnings base.
View the QCOM AI trading bot here: NFLX, KLAC, QCOM, PYPL, META - AI Trading Agent (5 Tickers), 15min
Thursday, February 5
Amazon.com (AMZN)
Amazon (AMZN) reports Q4 2025 after the close on February 5, with analysts looking for revenue of about 211.3 billion dollars—roughly 13 percent year‑over‑year growth—and EPS near 1.97 dollars, up about 5.7 percent. Q3 revenue was 180.2 billion dollars, up 13 percent year over year, but operating income was held back by special charges, while net income jumped 38 percent helped by a 9.5 billion dollar gain from revaluing its Anthropic stake. Amazon has already guided 2025 capex up to about 125 billion dollars and could exceed 150 billion dollars in 2026 as it invests heavily in AWS AI infrastructure, putting free‑cash‑flow pressure in the spotlight. This earnings release is critical for gauging whether higher‑margin AWS and advertising can outgrow core retail enough to support both aggressive capex and robust shareholder value creation.
View the AMZN AI trading bot here: Swing Trader: Search for Dips in Top 10 Giants, 60 min, (TA)
Shell (SHEL)
Shell (SHEL) will publish finalized Q4 2025 results on February 5, with a recent update note outlining an outlook for slightly lower marketing earnings and modest changes in production versus Q3. The company’s updated guidance calls for integrated‑gas production of 930–970 thousand barrels of oil equivalent per day, versus 934 thousand in Q3, and LNG liquefaction volumes of 7.5–7.9 million tonnes. Q3 adjusted earnings were about 5.4 billion dollars, with upstream production expected to dip slightly in Q4 before recovering within the guidance range. Investors will weigh Shell’s capital‑return framework and energy‑transition capex plans against this earnings backdrop to assess medium‑term cash‑flow resilience.
Linde (LIN)
Linde (LIN) remains a bellwether for industrial‑gas demand and a key player in decarbonization infrastructure, including hydrogen and carbon‑capture projects. Q4 2025 results will be parsed for volume trends across industrial end‑markets and contract pricing power, which together drive margin stability. Any updated commentary on long‑term clean‑energy project backlogs could influence how investors value the company’s growth runway into the 2030s.
ConocoPhillips (COP)
ConocoPhillips (COP) is coming off Q4 2024 earnings of 2.3 billion dollars, or 1.90 dollars per share, down from 3.0 billion dollars, or 2.52 dollars per share, a year earlier amid lower energy prices. On an adjusted basis, earnings were about 1.98 dollars per share, topping the 1.83 dollar FactSet consensus, and the company returned about 9.1 billion dollars to shareholders in 2024 while acquiring Marathon Oil. For 2025, ConocoPhillips guided production to 2.34–2.38 million barrels of oil equivalent per day, with a 10 billion dollar capital‑return target and over 1 billion dollars of anticipated integration synergies. The upcoming Q4 2025 print will show how well the integration is progressing and whether the company can maintain its returns‑focused posture in a choppy commodity environment.
KKR & Co. (KKR)
KKR (KKR) provides a read on private‑markets deal activity, valuations and fundraising as rates stabilize but remain higher than in the last cycle. Q4 2025 metrics on fee‑related earnings, performance income and realizations will be key to assessing how quickly deployment and exits are normalizing. The market will also focus on credit and infrastructure fundraising trends, which can diversify earnings and support a higher multiple over time.
View the KKR AI trading bot here: KKR - AI Trading Agent, 5min
Friday, February 6
Toyota Motor Corporation (TM)
Toyota (TM) closes out the week with a closely watched report that offers a global view on auto demand, FX and electrification strategy. Investing.com data indicate Q4 2025 EPS of about 10.9 dollars on revenue of roughly 81.44 billion dollars, far ahead of the prior year’s estimates, highlighting strong profitability momentum. More recently, Toyota posted Q2 2026 EPS of 4.85 dollars, beating expectations of 3.67 dollars by over 30 percent, reflecting robust execution and cost control. With another earnings call scheduled in mid‑February, investors will look for clarity on EV/hybrid mix, capital‑allocation policy and the sustainability of the company’s elevated margins.
Sector groupings and why this week matters
Technology and AI
This week’s tech slate—Palantir, AMD, Alphabet, Uber, Qualcomm and Amazon—offers a comprehensive look at AI monetization, cloud demand, digital ads and platform economics. Together, these prints can reset expectations for 2026 AI‑driven earnings power and clarify how much incremental capex is required to sustain growth, with implications across the broader market’s valuation.
Health care and biopharma
Merck, Pfizer, Amgen, Eli Lilly, AbbVie, Novartis and Novo Nordisk form a dense health‑care cluster that spans oncology, immunology and obesity drugs. With estimates cut for more than half of the health‑care index, but GLP‑1 leaders still growing rapidly, this week could sharply widen or narrow the sector’s dispersion and influence defensive‑growth positioning.
Energy, industrials and financials
Shell, ConocoPhillips, Linde, Toyota, Mizuho and KKR collectively reveal how global demand, commodity prices, industrial activity and private‑markets dynamics are evolving into 2026. Investors will gauge whether strong capital‑return programs and disciplined capex can be maintained if macro volatility persists, a key input for portfolio allocations between cyclicals and defensives.
Consumer and media
Disney and PepsiCo round out the consumer and media picture, testing the resilience of discretionary spending on experiences and staples demand in snacks and beverages. Their guidance on pricing, elasticity and content or marketing spend will help investors refine views on consumer strength and brand‑owner pricing power for 2026.
Across all groups, the upcoming Q4 2025 earnings and 2026 outlooks will likely drive meaningful stock‑specific moves and could also shift leadership between AI beneficiaries, health‑care growers and cash‑rich energy and industrial names.